These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 17144887)
1. Microvascular dysfunction: causative role in the association between hypertension, insulin resistance and the metabolic syndrome? Serné EH; de Jongh RT; Eringa EC; Ijzerman RG; de Boer MP; Stehouwer CD Essays Biochem; 2006; 42():163-76. PubMed ID: 17144887 [TBL] [Abstract][Full Text] [Related]
2. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Jonk AM; Houben AJ; de Jongh RT; Serné EH; Schaper NC; Stehouwer CD Physiology (Bethesda); 2007 Aug; 22():252-60. PubMed ID: 17699878 [TBL] [Abstract][Full Text] [Related]
3. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk. Chan JC; Tong PC; Critchley JA Semin Vasc Med; 2002 Feb; 2(1):45-57. PubMed ID: 16222595 [TBL] [Abstract][Full Text] [Related]
4. Vascular disease in the metabolic syndrome: do we need to target the microcirculation to treat large vessel disease? Krentz AJ; Clough G; Byrne CD J Vasc Res; 2009; 46(6):515-26. PubMed ID: 19571572 [TBL] [Abstract][Full Text] [Related]
5. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Correia ML; Rahmouni K Diabetes Obes Metab; 2006 Nov; 8(6):603-10. PubMed ID: 17026484 [TBL] [Abstract][Full Text] [Related]
6. Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. de Jongh RT; Serné EH; IJzerman RG; de Vries G; Stehouwer CD Circulation; 2004 Jun; 109(21):2529-35. PubMed ID: 15136505 [TBL] [Abstract][Full Text] [Related]
7. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Chapman MJ; Sposito AC Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of coronary dysfunction in obesity and insulin resistance. Knudson JD; Dincer UD; Bratz IN; Sturek M; Dick GM; Tune JD Microcirculation; 2007; 14(4-5):317-38. PubMed ID: 17613805 [TBL] [Abstract][Full Text] [Related]
10. Is insulin resistance the cause of the metabolic syndrome? Ferrannini E Ann Med; 2006; 38(1):42-51. PubMed ID: 16448988 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of hypertension in the cardiometabolic syndrome. Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G J Hypertens; 2009 Mar; 27(3):441-51. PubMed ID: 19262221 [TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome X: a review. Timar O; Sestier F; Levy E Can J Cardiol; 2000 Jun; 16(6):779-89. PubMed ID: 10863169 [TBL] [Abstract][Full Text] [Related]
18. Role of stress in the pathogenesis of the metabolic syndrome. Rosmond R Psychoneuroendocrinology; 2005 Jan; 30(1):1-10. PubMed ID: 15358437 [TBL] [Abstract][Full Text] [Related]
19. Hypertension-independent microvascular rarefaction in the obese Zucker rat model of the metabolic syndrome. Frisbee JC Microcirculation; 2005; 12(5):383-92. PubMed ID: 16020387 [TBL] [Abstract][Full Text] [Related]
20. Insulin resistance and upper-normal glucose levels in hypertension: a review. Cubeddu LX; Hoffmann IS J Hum Hypertens; 2002 Mar; 16 Suppl 1():S52-5. PubMed ID: 11986895 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]